TB-500 vs GHK-Cu Side-Effect Profile: Head-to-Head Comparison
HealthRX.com
No head-to-head side-effect data exists for these peptides
At a glance
- Head-to-head side-effect trial: none found
- Human studies of TB-500 itself identified by FDA: none [1]
- Reported reaction linked to a TB-500 product: one case in FDA's BPC-157 review, from a blended BPC-157 and TB-500 product [5]
- Risk FDA names for injectable TB-500: immunogenicity [1]
- Risk FDA names for injectable GHK-Cu: immunogenicity, limited human data [4]
- Topical GHK-Cu venous ulcer trial: 86 patients, 0.4% cream, no better than vehicle [3]
- Approval status: no FDA-approved drug contains either peptide [6][1]
Is there a head-to-head comparison of their side effects?
No study comparing the side effects of TB-500 and GHK-Cu against each other was found. TB-500 itself has not been given to a human in any published study FDA could locate [1]. GHK-Cu has been applied to human skin in small trials, but a 2026 systematic review that kept 64 records calls the human literature thin and fragmented: most randomized trials are small, run on facial cosmetic creams, and microneedle delivery has not been tested in an adequately powered registered human trial [7].
TB-500: what has actually been reported?
FDA's July 2026 evaluation, prepared for the Pharmacy Compounding Advisory Committee, searched PubMed, Embase, ClinicalTrials.gov and other sources and found no article in which TB-500 was given to a person; none of the three papers the nominator cited involved TB-500 in humans [1]. FDA's adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and its food and supplement complaint system, searched from January 1, 2004 to March 10, 2025, returned two cases involving a blended TB-500 and BPC-157 product, with no safety assessment attached [1]. FDA found no published case reports and no human pharmacokinetic or pharmacodynamic data for TB-500 by any route [1].
The closest thing to a reported reaction comes from FDA's review of BPC-157. A 40-year-old woman injected a research-use product containing BPC-157 plus TB-500 (5 mg/5 mg) subcutaneously twice daily and developed widespread skin hyperpigmentation and darkening of the gums within a week; the reaction came back when she re-tried the product two weeks later. Because the product held two peptides, FDA said it could not tell whether either one caused it [5].
FDA's stated concern for injectable TB-500 is immunogenicity, an immune reaction, potentially amplified by peptide aggregation and impurities [1]. FDA found no study of TB-500 immunogenicity or aggregation, and no nonclinical toxicity studies of TB-500 [1].
One clarification matters here. TB-500 is a synthetic 7-amino-acid, N-acetylated fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4, not the full protein [1]. Trials of recombinant full-length thymosin beta-4 tested a different molecule: in a phase 1 single-dose trial of 54 healthy volunteers who received intravenous recombinant human thymosin beta-4 or placebo, adverse events were mild to moderate, with no dose-limiting toxicity and no serious adverse events [8]. Those results do not describe TB-500.
GHK-Cu: what the human data show
Topical copper peptide products are sold as cosmetics when they are marketed for cosmetic use. Cosmetics and cosmetic ingredients other than color additives do not need FDA approval before they are sold, and whether a product is a cosmetic or a drug depends on its intended use: claims to treat disease or to change the structure or function of the body make it a drug [9].
The human trials are small and mostly tested creams. In a randomized trial, patients whose skin around the mouth had been resurfaced with a CO2 laser used post-treatment skin care with or without GHK-Cu; 13 patients completed. Computer analysis and blinded evaluators found no significant difference between groups in how quickly redness resolved, in wrinkles, or in overall skin quality, while a patient questionnaire showed a significant difference in overall skin quality favouring GHK-Cu (P=.04) [2].
In an 86-patient randomized, evaluator-blinded trial of venous stasis ulcers, a 0.4% tripeptide copper complex cream was no different from an inert vehicle placebo on ulcer size, while silver sulfadiazine 1% did reduce ulcer size [3].
Injectable GHK-Cu is a separate case. FDA's page on bulk substances that may raise significant safety risks states that compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity because of the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations [4]. Injectable GHK-Cu is not in category 1 of FDA's compounding list; it sits in the nominated-but-withdrawn table on that safety-risk page [4][6].
How the two profiles stack up
On published human exposure, the gap is wide: no study of TB-500 in people was found by FDA, while topical GHK-Cu has been applied to human skin in two small randomized trials [1][2][3]. FDA describes human data on injectable GHK-Cu as limited [4].
On named risks, both injectable peptides carry an immunogenicity concern that FDA describes in similar terms: aggregation and peptide-related impurities with the potential for an immune reaction [1][4]. Neither has a reported rate of reactions in people, and no adverse-event rates were found for topical GHK-Cu products in the trials checked [2][3][4].
Questions worth asking
Regulatory status, briefly
Neither peptide is an FDA-approved drug [6][1]. No FDA-approved drug contains GHK-Cu, and it should not be confused with copper histidinate (Zycubo, approved January 12, 2026 for Menkes disease in children), a different compound [6][10]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [11].
TB-500 is named on WADA's Prohibited List in S2.3 as thymosin-beta4 and its derivatives, prohibited at all times, and it appears on both the 2026 and 2027 Lists [12][13]. GHK-Cu is not named on the 2026 or 2027 List, but the 2027 notes say that peptides not specifically named may still be prohibited [12][14].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Does TB-500 have any human safety data?
Is GHK-Cu safer than TB-500?
What does FDA say about injectable GHK-Cu?
Has anyone reported a reaction to a TB-500 product?
Is topical copper peptide FDA-approved?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
What does TB500 do to the body?
TB-500's effects in the body are not established. It is a synthetic 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4, and FDA found no human pharmacokinetic or pharmacodynamic data for it by any route. Its effects in people are not established.
Are there any risks to taking GHK-Cu?
Yes, FDA flags a potential immune-reaction risk for injectable GHK-Cu, because compounded injectable products may carry immunogenicity risk from aggregation and peptide-related impurities. FDA says there are limited data in humans to inform its safety. For topical GHK-Cu, no adverse-event rates were found in the trials checked.
Does TB500 affect your heart?
No data on TB-500 and the heart were found. FDA found no human pharmacokinetic or pharmacodynamic data and no nonclinical toxicity studies for TB-500, and no published case reports. Whether TB-500 affects the heart is not established.
References
Show all 14 referencesHide references
- U.S. Food and Drug Administration.
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9.
- Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293.
- Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
- Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- World Anti-Doping Agency.